ReviewCurrent protein & peptide science2026
Messenger RNA Nanomedicine: Innovations and Future Directions.
Review in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- mRNA-Encoded antibodies as a next-generation therapeutic paradigm: a rapid and adaptive platform for the prevention and treatment of emerging and re-emerging infectious diseases - A critical review.Immunologic research · 2026Review
- Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives.Frontiers in genetics · 2025Review
- Scaling transformers to high-dimensional sparse data: a Reformer-BERT approach for large-scale classification.Frontiers in artificial intelligence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With its high potential, mRNA nanomedicine has become one of the transformative frontiers of modern therapeutic strategies for treating and preventing a wide array of diseases. This review article covers recent developments in mRNA nanomedicine and its prospects in terms of innovations in drug delivery systems, stability improvements, and targeted therapeutic applications. The versatility of mRNA means that almost any protein can potentially be encoded into it, making it a powerhouse for vaccines, gene editing, and protein replacement therapies. Recent breakthroughs in nanoparticle technology have significantly enhanced mRNA molecules' delivery efficiency and stability, surmounting previous barriers concerning rapid degradation and immune system activation. It has been developed innovations such as LNPs, polymer-based carriers, and hybrid nanocarriers have been central to the success of targeted delivery and the sustained release of mRNA. This review further underlines the potential of mRNA nanomedicine for oncological, infectious, and genetic diseases by highlighting ongoing clinical trials, emerging therapeutic paradigms, and future directions that lay much emphasis on delivery platform optimization, mRNA stability, and broadening the scope of mRNA nanomedicine therapy. With the power of emerging technologies and solving present challenges, mRNA nanomedicine has a vast potential to revolutionize the future landscape of personalized medicine and targeted therapies.
Indexed as
Identifiers
40277053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.